190 related articles for article (PubMed ID: 25851619)
1. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis.
Plautz WE; Sekhar Pilli VS; Cooley BC; Chattopadhyay R; Westmark PR; Getz T; Paul D; Bergmeier W; Sheehan JP; Majumder R
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):816-828. PubMed ID: 29419409
[TBL] [Abstract][Full Text] [Related]
4. The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X.
Misenheimer TM; Buyue Y; Sheehan JP
Biochemistry; 2007 Jul; 46(26):7886-95. PubMed ID: 17563121
[TBL] [Abstract][Full Text] [Related]
5. The regulation of factor IXa by supersulfated low molecular weight heparin.
Misenheimer TM; Sheehan JP
Biochemistry; 2010 Nov; 49(46):9997-10005. PubMed ID: 20945941
[TBL] [Abstract][Full Text] [Related]
6. Residues Tyr253 and Glu255 in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa.
Izaguirre G; Olson ST
J Biol Chem; 2006 May; 281(19):13424-13432. PubMed ID: 16517611
[TBL] [Abstract][Full Text] [Related]
7. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
Lu Q; Yang L; Manithody C; Wang X; Rezaie AR
Biochemistry; 2015 Jun; 54(24):3814-21. PubMed ID: 26023895
[TBL] [Abstract][Full Text] [Related]
8. Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease.
Izaguirre G; Aguila S; Qi L; Swanson R; Roth R; Rezaie AR; Gettins PG; Olson ST
J Biol Chem; 2014 Dec; 289(49):34049-64. PubMed ID: 25331949
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
10. Factor IXa variants resistant to plasma inhibitors enhance clot formation in vivo.
Ivanciu L; Arruda VR; Camire RM
Blood; 2023 Apr; 141(16):2022-2032. PubMed ID: 36724452
[TBL] [Abstract][Full Text] [Related]
11. Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays.
Yu Y; Millar CM
J Thromb Haemost; 2014 Jan; 12(1):62-70. PubMed ID: 24215160
[TBL] [Abstract][Full Text] [Related]
12. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin.
Yuan QP; Walke EN; Sheehan JP
Biochemistry; 2005 Mar; 44(9):3615-25. PubMed ID: 15736971
[TBL] [Abstract][Full Text] [Related]
13. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B.
Rallapalli PM; Kemball-Cook G; Tuddenham EG; Gomez K; Perkins SJ
J Thromb Haemost; 2013 Jul; 11(7):1329-40. PubMed ID: 23617593
[TBL] [Abstract][Full Text] [Related]
14. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity.
Chang J; Jin J; Lollar P; Bode W; Brandstetter H; Hamaguchi N; Straight DL; Stafford DW
J Biol Chem; 1998 May; 273(20):12089-94. PubMed ID: 9575152
[TBL] [Abstract][Full Text] [Related]
15. Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin.
Izaguirre G; Zhang W; Swanson R; Bedsted T; Olson ST
J Biol Chem; 2003 Dec; 278(51):51433-40. PubMed ID: 14532267
[TBL] [Abstract][Full Text] [Related]
16. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Nummi V; Jouppila A; Lassila R
Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
[TBL] [Abstract][Full Text] [Related]
17. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.
Buyue Y; Whinna HC; Sheehan JP
Blood; 2008 Oct; 112(8):3234-41. PubMed ID: 18647957
[TBL] [Abstract][Full Text] [Related]
18. The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D.
Dementiev A; Swanson R; Roth R; Isetti G; Izaguirre G; Olson ST; Gettins PGW
J Biol Chem; 2013 Nov; 288(47):33611-33619. PubMed ID: 24068708
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.
Johnson DJ; Langdown J; Huntington JA
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):645-50. PubMed ID: 20080729
[TBL] [Abstract][Full Text] [Related]
20. Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite.
Buyue Y; Sheehan JP
Blood; 2009 Oct; 114(14):3092-100. PubMed ID: 19414859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
